Abbott (NYSE: ABT), a global healthcare company, announced on Monday that it has received approval from the United States Food and Drug Administration (FDA) for its Portico with FlexNav transcatheter aortic valve replacement system for the treatment of people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
The company continues to provide range of structural heart solutions that include innovative, minimally invasive therapies to repair or replace diseased or damaged heart valves or close openings in the heart with the new TAVR (also referred to as TAVI, or transcatheter aortic valve implantation) advancement.
Raj Makkar, MD, associate director of Interventional Technologies at Cedars-Sinai's Smidt Heart Institute, said, 'For people in the US suffering from aortic stenosis and unable to have surgery, the Portico with FlexNav system offers a safe and effective treatment option.'
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data